<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Pethidine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00454</strong>&#160; (APRD00074)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00454/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00454/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00454.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00454.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00454.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00454.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00454.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00454">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Isonipeca&#239;ne</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Meperidine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>USAN</td></tr><tr><td>Pethidin</td><td>German</td><td>INN</td></tr><tr><td>P&#233;thidine</td><td>French</td><td>INN</td></tr><tr><td>Pethidinum</td><td>Latin</td><td>INN</td></tr><tr><td>Petidina</td><td>Spanish</td><td>INN</td></tr><tr><td>Petydyna</td><td>Polish</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Sauteralgyl</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Spasmedal</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Spasmodolin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Meperidine hydrochloride</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT001046/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT001046/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT001046">DBSALT001046</a></td>
      </tr>
      <tr>
        <td>
          <strong>Pethidine hydrochloride</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000628/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000628/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: WCNLCIJMFAJCPX-UHFFFAOYSA-N</li>
              <li>Monoisotopic Mass: 283.13390666</li>
              <li>Average Mass: 283.794</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000628">DBSALT000628</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Demerol</td><td>sanofi-aventis</td></tr><tr><td>Dolantin</td><td>sanofi-aventis</td></tr><tr><td>Dolcontral</td><td>mibe</td></tr><tr><td>Dolosal</td><td>Crist&#225;lia</td></tr><tr><td>Dolsin</td><td>Biotika</td></tr><tr><td>Lydol</td><td>Sopharma</td></tr><tr><td>Mialgin</td><td>Zentiva</td></tr><tr><td>Petidin</td><td>Nycomed</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Pamergan P100</td><td>Pethidine and Promethazine</td></tr><tr><td>Weak Pethilorfan</td><td>Pethidine and Levallorphan</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/adjuvants">Adjuvants</a></li></ul></td></tr><tr><th>CAS number</th><td>57-42-1</td></tr><tr><th>Weight</th><td>Average: 247.3327<br>Monoisotopic: 247.157228921</td></tr><tr><th>Chemical Formula</th><td>C<sub>15</sub>H<sub>21</sub>NO<sub>2</sub></td></tr><tr><th>InChI Key</th><td>XADCESSVHJOZHK-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C15H21NO2/c1-3-18-14(17)15(9-11-16(2)12-10-15)13-7-5-4-6-8-13/h4-8H,3,9-12H2,1-2H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">ethyl 1-methyl-4-phenylpiperidine-4-carboxylate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCOC(=O)C1(CCN(C)CC1)C1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Piperidines</td></tr><tr><th>Subclass</th><td>Phenylpiperidines</td></tr><tr><th>Direct parent</th><td>Phenylpiperidines</td></tr><tr><th>Alternative parents</th><td>Phenylacetic Acid Derivatives; Piperidinecarboxylic Acids; Tertiary Amines; Carboxylic Acid Esters; Ethers; Enolates; Polyamines</td></tr><tr><th>Substituents</th><td>phenylacetate; piperidinecarboxylic acid; benzene; carboxylic acid ester; tertiary amine; ether; enolate; carboxylic acid derivative; polyamine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used to control moderate to severe pain.</td></tr><tr><th>Pharmacodynamics</th><td>Meperidine is a synthetic opiate agonist belonging to the phenylpiperidine class. Meperidine may produce less smooth muscle spasm, constipation, and depression of the cough reflex than equivalent doses of morphine. The onset of action is lightly more rapid than with morphine, and the duration of action is slightly shorter. The chemical structure of meperidine is similar to local anesthetics. Meperidine is recommended for relief of moderate to severe acute pain and has the unique ability to interrupt postoperative shivering and shaking chills induced by amphotericin B. Meperidine has also been used for intravenous regional anesthesia, peripheral nerve blocks and intraarticular, epidural and spinal analgesia. Meperidine is considered a second-line agent for the treatment of acute pain.</td></tr><tr><th>Mechanism of action</th><td>Meperidine is primarily a kappa-opiate receptor agonist and also has local anesthetic effects. Meperidine has more affinity for the kappa-receptor than morphine. Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.</td></tr><tr><th>Absorption</th><td>The oral bioavailability of meperidine in patients with normal hepatic function is 50-60% due to extensive first-pass metabolism. Bioavailability increases to 80-90% in patients with hepatic impairment (e.g. liver cirrhosis). Meperidine is less than half as effective when administered orally compared to parenteral administration. One study reported that 80-85% of the drug administered intramuscularly was absorbed within 6 hours of intragluteal injection in health adults; however, inter-individual variation and patient-specific variable appear to cause considerable variations in absorption upon IM injection. </td></tr><tr><th>Volume of distribution</th><td><p>Meperidine crosses the placenta and is distributed into breast milk.</p></td></tr><tr><th>Protein binding</th><td>60-80% bound to plasma proteins, primarily albumin and &#945;<sub>1</sub>-acid glycoprotein. The presence of cirrhosis or active viral hepatitis does not appear to affect the extent of protein binding. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Meperidine is metabolized in the liver by hydrolysis to meperidinic acid followed by partial conjugation with glucuronic acid. Meperidine also undergoes N-demethylation to normeperidine, which then undergoes hydrolysis and partial conjugation. Normeperidine is about half as potent as meperidine, but it has twice the CNS stimulation effects.</p></td></tr><tr><th>Route of elimination</th><td>Excreted in the urine. The proportion of drug that is excreted unchanged or as metabolites is dependent on pH. When urine pH is uncontrolled, 5-30% of the meperidine dose is excreted as normeperidine and approximately 5% is excreted unchanged. Meperidine and normeperidine are found in acidic urine, while the free and conjugated forms of meperidinic and normperidinic acids are found in alkaline urine. </td></tr><tr><th>Half life</th><td>Initial distribution phase (t<sub>1/2 &#945;</sub>) = 2-11 minutes; terminal elimination phase (t<sub>1/2 &#946;</sub>) =  3-5 hours. In patients with hepatic dysfunction (e.g. liver cirrhosis or active viral hepatitis) the t<sub>1/2 &#946;</sub> is prolonged to 7-11 hours.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9947</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9876</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6683</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7821</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.5174</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.5401</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.6375</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8593</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8826</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5073</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6897</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6691</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.7415</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7635</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6876</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.5547</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8694
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8355
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9145
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.1526 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8593
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.5813
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Hospira inc</li>
<li>Sanofi aventis us llc</li>
<li>Abbott laboratories pharmaceutical products div</li>
<li>Astrazeneca lp</li>
<li>Baxter healthcare corp anesthesia and critical care</li>
<li>Baxter healthcare corp anesthesia critical care</li>
<li>Elkins sinn div ah robins co inc</li>
<li>International medication systems ltd</li>
<li>Parke davis div warner lambert co</li>
<li>Watson laboratories inc</li>
<li>International medication system</li>
<li>Mallinckrodt chemical inc</li>
<li>Roxane laboratories inc</li>
<li>Barr laboratories inc</li>
<li>Caraco pharmaceutical laboratories ltd</li>
<li>Duramed pharmaceuticals inc sub barr laboratories inc</li>
<li>Mallinckrodt inc</li>
<li>Mikah pharma llc</li>
<li>Mikart inc</li>
<li>Mutual pharmaceutical co inc</li>
<li>Vintage pharmaceuticals inc</li>
<li>Wyeth ayerst laboratories</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.astrazeneca.ca">AstraZeneca Inc.</a></li>
<li>Barr Pharmaceuticals</li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.bayerhealthcare.com">Bayer Healthcare</a></li>
<li><a href="http://www.caraco.com">Caraco Pharmaceutical Labs</a></li>
<li>D.M. Graham Laboratories Inc.</li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.hawkinsinc.com">Hawkins Inc.</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.mallinckrodt.com">Mallinckrodt Inc.</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pharmedium.com">Pharmedium</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li><a href="http://www.roxane.com">Roxane Labs</a></li>
<li><a href="http://www.sanofi-aventis.com">Sanofi-Aventis Inc.</a></li>
<li>Vintage Pharmaceuticals Inc.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Solution</td><td>Intravenous</td><td>10 mg/ml</td></tr><tr><td>Solution</td><td>Oral</td><td>50 mg/5ml</td></tr><tr><td>Solution</td><td>Parenteral</td><td>25 mg/ml, 50 mg/ml, 75 mg/ml, 100 mg/ml</td></tr><tr><td>Tablet</td><td>Oral</td><td>50 mg, 100 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB06274">Alvimopan</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB00477">Chlorpromazine</a></td><td>Increased sedation and hypotension</td></tr><tr><td><a href="/drugs/DB06700">Desvenlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00843">Donepezil</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Increases levels of Meperidine via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. </td></tr><tr><td><a href="/drugs/DB00674">Galantamine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01247">Isocarboxazid</a></td><td>Potentially fatal adverse effects</td></tr><tr><td><a href="/drugs/DB00951">Isoniazid</a></td><td>Possible episodes of hypotension</td></tr><tr><td><a href="/drugs/DB01171">Moclobemide</a></td><td>Increased CNS toxicity (can cause death)</td></tr><tr><td><a href="/drugs/DB00780">Phenelzine</a></td><td>Potentially fatal adverse effects</td></tr><tr><td><a href="/drugs/DB01367">Rasagiline</a></td><td>Increased risk of serotonin syndrome. Concomitant use should be avoided.</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Ritonavir increases the levels of analgesic</td></tr><tr><td><a href="/drugs/DB00989">Rivastigmine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01037">Selegiline</a></td><td>Potentially fatal adverse effects</td></tr><tr><td><a href="/drugs/DB01105">Sibutramine</a></td><td>Possible serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir may increase the adverse/toxic effects of Meperidine. Consider alternate therapy or monitor for Meperidine toxicity during concomitant use. </td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>Increased risk of serotonin syndrome. Concomitant use should be avoided.</td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. </td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Meperidine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00285">Venlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00315">Zolmitriptan</a></td><td>Use of two serotonin modulators, such as zolmitriptan and meperidine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals. Avoid alcohol.</li></ul></td></tr></tbody></table>